CRMD vs NRIX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
NRIX Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Growth & Margin, Momentum & Technical while CRMD counters with relative strength in Valuation, Options & Structure. Fundamentally, CRMD trades at 49.0x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus NRIX at N/M Forward P/E and 41.3% operating margin (+8426.3% YoY). In options structure, CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | NRIX Revenue | CRMD Op. Margin | NRIX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | N/A | -6250.4% | N/A | CRMD |
| FY2019 | $0M | $30M | -7416.3% | -71.5% | NRIX |
| FY2020 | $0M | $20M | -11378.4% | -364.7% | NRIX |
| FY2021 | $0M | $30M | -15417.5% | -396.3% | NRIX |
| FY2022 | $0M | $40M | -46819.9% | -476.0% | NRIX |
| FY2023 | N/A | $80M | N/A | -201.4% | NRIX |
| FY2024 | $40M | $50M | -51.4% | -390.5% | CRMD |
| FY2025 | $310M | $80M | 48.2% | -340.2% | CRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | NRIX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $384.7M | $1.7B | Larger Scale | NRIX |
| Trailing P/E Ratio Valuation | 2.4x | 6.4x | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 49.0x | N/M | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -47.7% | +8426.3% | Higher Growth | NRIX |
| Operating Margin (TTM) Profitability | 41.0% | 41.3% | Higher Margin | NRIX |
| Net Profit Margin Profitability | 15.5% | 42.0% | Higher Margin | NRIX |
| Return on Equity (ROE) Capital Efficiency | 15.3% | 44.0% | Higher ROE | NRIX |
| 52-Week Range Position Momentum | 3% ($5โ$13) | 18% ($12โ$28) | Stronger Trend | NRIX |
| Beta / 30D Volatility Risk Regime | 1.20ฮฒ ยท 107% Vol | 0.94ฮฒ ยท 141% Vol | Lower Realized Risk | CRMD |
| Unified Institutional Score Composite Signal | 53.2 / 100 (HOLD) | 51.5 / 100 (HOLD) | Higher Composite | CRMD |